Xadago
safinamide
Keep this leaflet. You may need to read it again.
If you have any further questions, ask your doctor.
This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4.
What Xadago is and what it is used for
What you need to know before you take Xadago
How to take Xadago
Possible side effects
How to store Xadago
Contents of the pack and other information
Xadago is a medicine that contains the active substance safinamide. It acts to increase the level of a substance called dopamine in the brain, which is involved in the control of movement and is present in reduced amounts in the brain of patients with Parkinson’s disease. Xadago is used for the treatment of Parkinson’s disease in adults.
In mid- to late-stage patients experiencing sudden switches between being “ON” and able to move and being “OFF” and having difficulties moving about, Xadago is added to a stable dose of the medicine called levodopa alone or in combination with other medicines for Parkinson’s disease.
If you are allergic to safinamide or any of the other ingredients of this medicine (listed in section 6).
If you are taking any of the following medicines:
Monoamine oxidase (MAO) inhibitors such as selegiline, rasagiline, moclobemide, phenelzine, isocarboxazid, tranylcypromine (e.g. for treatment of Parkinson’s disease or depression, or used for any other condition).
Pethidine (a strong pain killer).
You must wait at least 7 days after stopping Xadago treatment before starting treatment with MAO inhibitors or pethidine.
If you have been told that you have severe liver problems
If you have an eye condition which might put you at risk of potential damage to your retina (the light sensitive layers at the back of your eyes), e.g. albinism (lack of pigment in your skin and eyes), retinal degeneration (loss of cells from light sensitive layer at the back of the eye), or uveitis (inflammation inside of the eye), inherited retinopathy (inherited disorders of the vision), or severe progressive diabetic retinopathy (a progressive decrease of the vision due to diabetes).
Talk to your doctor before taking Xadago
If you have liver problems
Patients and carers should be made aware that certain compulsive behaviours such as compulsions, obsessive thoughts, pathological gambling, increased libido, hypersexuality, impulsive behaviour and compulsive spending or buying have been reported with other medicines for Parkinson’s disease.
Uncontrollable jerky movements may occur or worsen when Xadago is used together with levodopa.
Xadago is not recommended for use in children and adolescents, below 18 years old due to the lack of data on safety and efficacy in this population.
Tell your doctor or pharmacist if you are taking or have recently taken or might take any other medicines. Ask your doctor for advice before taking any of the following medicines together with Xadago:
Cold or cough remedies containing dextromethorphan, ephedrine or pseudoephedrine
Medicines called selective serotonin reuptake inhibitors (SSRIs) typically used to treat anxiety disorders, and some personality disorders (e.g. fluoxetine or fluvoxamine)
Medicines called serotonin–norepinephrine reuptake inhibitors (SNRIs), used in the treatment of major depression and other mood disorders, such as venlafaxine
Medicines for high cholesterol such as rosuvastatin, pitavastatin, pravastatin
Fluoroquinolone antibiotic such as ciprofloxacin
Medicines that affect the immune system such as methotrexate
Medicines to treat metastatic carcinoma such as topotecan
Medicine to treat pain and inflammation such as diclofenac
Medicines to treat type 2 diabetes such as glyburide, metformin
Medicines to treat virus infection such as aciclovir, ganciclovir
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
Pregnancy
Xadago should not be used during pregnancy or by women of childbearing potential not practicing adequate contraception.
Breast Feeding
Xadago is likely to be excreted in breast milk. Xadago should not be used during breast-feeding.
Somnolence and dizziness may occur during safinamide treatment; you should be cautious about operating hazardous machines or driving, until you are reasonably certain that Xadago does not affect you in any way.
Ask your doctor for advice prior to driving or using machines.
Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.
The recommended starting dose of Xadago is one 50 mg tablet that may be increased to one 100 mg tablet, taken once daily preferably in the morning by mouth with water. Xadago may be taken with or without food.
If you suffer from moderately reduced liver function, you should not take more than 50 mg a day; your doctor will advise if this applies to you.
If you have taken too many Xadago tablets, you may develop raised blood pressure, anxiety, confusion, forgetfulness, sleepiness, lightheadedness; feel sick or be sick; dilated pupils or develop involuntary jerky movements. Contact your doctor immediately and take the Xadago pack with you.
Do not take a double dose to make up for a forgotten dose. Skip the missed dose and take the next dose at the time you normally take it.
Do not stop taking Xadago without first talking to your doctor.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Seek medical advice in case of hypertensive crisis (very high blood pressure, collapse), neuroleptic malignant syndrome (confusion, sweating, muscle rigidity, hyperthermia, increase level of enzyme creatine kinase in your blood), serotonin syndrome (confusion, hypertension, muscle stiffness, hallucinations), and hypotension.
The following side effects have been reported in patients at a mid- to late-stage of Parkinson’s disease (patients taking safinamide as add-on to levodopa alone or in combination with other medicines for Parkinson’s disease):
swelling of your feet, pain, feeling hot, weight loss, weight gain, abnormal blood tests, high fat in your blood, increased sugar in your blood, abnormal ECG, liver function test abnormal, abnormal urine tests, blood pressure decreased, blood pressure increased, abnormal eye test, fracture of your foot.
national | reporting | system |
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via
. By reporting side effects, you can help provide more information on the safety
of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after “EXP” The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
The active substance is safinamide. Each tablet contains 50 mg or 100 mg of safinamide (as methansulfonate).
The other ingredients are:
Tablet core: microcrystalline cellulose, crospovidone type A, magnesium stearate, silica colloidal anhydrous
Tablet coating: hypromellose, macrogol (6000), titanium dioxide (E171), iron oxide red (E172), mica (E555).
Xadago 50 mg are orange to copper, round, biconcave film-coated tablets of 7 mm diameter with metallic gloss, embossed with “50” on one side of the tablet.
Xadago 100 mg are orange to copper, round, biconcave film-coated tablets 9 mm diameter with metallic gloss, embossed with “100” on one side of the tablet.
Xadago is supplied in packs containing 14, 28, 30, 90 or 100 film coated tablets. Not all pack sizes may be marketed.
Zambon S.p.A.
Via Lillo del Duca 10 20091 Bresso (MI) Italy
Tel: +39 02665241
Fax: +39 02 66501492
Email: info.zambonspa@zambongroup.com
Catalent Germany Schorndorf GmbH Steinbeisstrasse 2
D- 73614 Schorndorf Germany
Zambon S.p.A.
Via della Chimica, 9 36100 Vicenza
Italy
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Zambon France S.A.
Tél: + 33 (0)1 58 04 41 41
Teл./Tel/Τηλ/Sími: + 39 02665241
Zambon Italia S.r.l. Tel: + 39 02665241
Zambon Nederland B.V. Tel: + 31 (0) 20 3085185
Zambon GmbH
Tel: 00800 92626633
Zambon - Produtos Farmacêuticos, Lda. Tel: + 351 217 600 952 / 217 600 954
Zambon, S.A.U.
Tel: + 34 93 544 64 00
Desitin Pharma spol. s r.o. Tel: + 420 222 245 375
Innovis Pharma A.E.B.E.
Τηλ:+ 30 216 200 5600
UAB „Norameda“ Tel: + 370 5 2306499